Tumor microvascular changes in antiangiogenic treatment: Assessment by magnetic resonance contrast media of different molecular weights

To test magnetic resonance (MR) contrast media of different molecular weights (MWs) for their potential to characterize noninvasively microvascular changes in an experimental tumor treatment model.

[1]  K. Claffey,et al.  Regulation of VEGF/VPF expression in tumor cells: Consequences for tumor growth and metastasis , 1996, Cancer and Metastasis Reviews.

[2]  Robert C. Brasch,et al.  MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model , 2003, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  M. Itoman,et al.  Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. , 2002, Biochemical and biophysical research communications.

[4]  C. Brock,et al.  Anti-angiogenic strategies and vascular targeting in the treatment of lung cancer , 2002, European Respiratory Journal.

[5]  T. K. Hunt,et al.  Noninvasive assessment of wound-healing angiogenesis with contrast-enhanced MRI. , 2002, Academic radiology.

[6]  K. Hoekman.  SU6668, a multitargeted angiogenesis inhibitor. , 2001, Cancer journal.

[7]  D M Shames,et al.  MR imaging characterization of microvessels in experimental breast tumors by using a particulate contrast agent with histopathologic correlation. , 2001, Radiology.

[8]  M. Karkkainen,et al.  Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis , 2000, Oncogene.

[9]  G. Martiny-Baron,et al.  Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model. , 2000, Cancer research.

[10]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[11]  I. Fidler,et al.  Blockade of the epidermal growth factor receptor signaling by a novel tyrosine kinase inhibitor leads to apoptosis of endothelial cells and therapy of human pancreatic carcinoma. , 2000, Cancer research.

[12]  T. Veikkola,et al.  Regulation of angiogenesis via vascular endothelial growth factor receptors. , 2000, Cancer research.

[13]  J. Cherrington,et al.  New paradigms for the treatment of cancer: the role of anti-angiogenesis agents. , 2000, Advances in cancer research.

[14]  T. Helbich,et al.  Prostate cancer tumor grade differentiation with dynamic contrast-enhanced MR imaging in the rat: comparison of macromolecular and small-molecular contrast media--preliminary experience. , 1999, Radiology.

[15]  J L Evelhoch,et al.  Key factors in the acquisition of contrast kinetic data for oncology , 1999, Journal of magnetic resonance imaging : JMRI.

[16]  S. Arii,et al.  Implication of vascular endothelial growth factor in the development and metastasis of human cancers. , 1999, Human cell.

[17]  P M Carpenter,et al.  Characterization of N‐ethyl‐N‐nitrosourea‐induced malignant and benign breast tumors in rats by using three MR contrast agents , 1999, Journal of magnetic resonance imaging : JMRI.

[18]  D M Shames,et al.  Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media. , 1998, AJR. American journal of roentgenology.

[19]  C. Higgins,et al.  Histologic confirmation of microvascular hyperpermeability to macromolecular MR contrast medium in reperfused myocardial infarction , 1998, Journal of magnetic resonance imaging : JMRI.

[20]  D. Cheresh,et al.  Disruption of Angiogenesis by PEX, a Noncatalytic Metalloproteinase Fragment with Integrin Binding Activity , 1998, Cell.

[21]  C. Angeletti,et al.  Angiogenesis as a prognostic indicator of survival in non-small-cell lung carcinoma: a prospective study. , 1997, Journal of the National Cancer Institute.

[22]  G. Palade,et al.  Neovasculature induced by vascular endothelial growth factor is fenestrated. , 1997, Cancer research.

[23]  N. van Bruggen,et al.  Assessing tumor angiogenesis using macromolecular MR imaging contrast media , 1997, Journal of magnetic resonance imaging : JMRI.

[24]  C K Kuhl,et al.  Breast neoplasms: T2* susceptibility-contrast, first-pass perfusion MR imaging. , 1997, Radiology.

[25]  T. Roberts,et al.  Physiologic measurements by contrast‐enhanced MR imaging: Expectations and limitations , 1997, Journal of magnetic resonance imaging : JMRI.

[26]  A. Ullrich,et al.  Flk-1 as a target for tumor growth inhibition. , 1996, Cancer research.

[27]  R. Brasch,et al.  Contrast-enhanced MR imaging assessment of tumor capillary permeability: effect of irradiation on delivery of chemotherapy. , 1996, Radiology.

[28]  R. Brasch,et al.  Quantification of liver blood volume: comparison of ultra short ti inversion recovery echo planar imaging (ulstir‐epi), with dynamic 3d‐gradient recalled echo imaging , 1995, Magnetic resonance in medicine.

[29]  L. Ellis,et al.  Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. , 1995, Cancer research.

[30]  H. Dvorak,et al.  Ultrastructural localization of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) to the abluminal plasma membrane and vesiculovacuolar organelles of tumor microvascular endothelium. , 1995, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[31]  G. Martiny-Baron,et al.  VEGF-mediated tumour angiogenesis: a new target for cancer therapy. , 1995, Current opinion in biotechnology.

[32]  G. Adam,et al.  Dynamic contrast‐enhanced MR imaging of the upper abdomen: Enhancement properties of gadobutrol, gadolinium‐DTPA‐polylysine, and gadolinium‐DTPA‐cascade‐polymer , 1994, Magnetic resonance in medicine.

[33]  D. Cheresh,et al.  Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. , 1994, Cell.

[34]  D M Shames,et al.  Measurement of capillary permeability to macromolecules by dynamic magnetic resonance imaging: A quantitative noninvasive technique , 1993, Magnetic resonance in medicine.

[35]  R. Brasch,et al.  Differentiation of alveolitis and pulmonary fibrosis with a macromolecular MR imaging contrast agent. , 1992, Radiology.

[36]  C. Sotak,et al.  Quantitative dependence of MR signal intensity on tissue concentration of Gd(HP-DO3A) in the nephrectomized rat. , 1992, Magnetic resonance imaging.

[37]  M. Ogan,et al.  Albumin labeled with Gd-DTPA: an intravascular contrast-enhancing agent for magnetic resonance blood pool imaging: preparation and characterization. , 1987, Investigative radiology.

[38]  H. Weinmann,et al.  Pharmacokinetics of GdDTPA/dimeglumine after intravenous injection into healthy volunteers. , 1984, Physiological chemistry and physics and medical NMR.